I agree that this site is using cookies. You can find further informations here.
X
Lech-Marańda, Ewa
147  results:
Search for persons X
?
1

Pirtobrutinib, a highly selective, non-covalent (reversible..:

Wierda, William G ; Shah, Nirav N ; Cheah, Chan Y...
The Lancet Haematology.  , 2024
Link: https://doi.org/10.1016/..
 
?
2

Characteristics of patients with newly diagnosed hematologi..:

Kępski, Jarosław ; Szmit, Sebastian ; Lech-Marańda, Ewa
Frontiers in Oncology.  14 (2024)  - p. , 2024
Link: https://doi.org/10.3389/..
 
?
3

Asciminib stands out as the superior tyrosine kinase inhibi..:

Domka, Krzysztof ; Dąbkowska, Agnieszka ; Janowska, Martyna...
Haematologica.  , 2024
Link: https://doi.org/10.3324/..
 
?
4

Real-World Outcome and Prognostic Factors in MDS Patients T..:

Wiśniewski, Kamil ; Pruszczyk-Matusiak, Katarzyna ; Puła, Bartosz..
Cancers.  16 (2024)  7 - p. 1333 , 2024
Link: https://doi.org/10.3390/..
 
?
5

P1103: OBINUTUZUMAB INDUCTION AND MAINTENANCE IN PATIENTS W..:

Wróbel, Tomasz ; Kalicinska, Elzbieta ; Maciej Zaucha, Jan...
HemaSphere.  7 (2023)  S3 - p. e4339598 , 2023
Link: https://doi.org/10.1097/..
 
?
6

Clinical outcomes of patients with myelofibrosis after imme..:

Mesa, Ruben ; Verstovsek, Srdan ; Platzbecker, Uwe...
Haematologica.  109 (2023)  2 - p. 676-681 , 2023
Link: https://doi.org/10.3324/..
 
?
7

P1108: EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-C..:

Scarfò, Lydia ; Patel, Manish R. ; Eyre, Toby A....
HemaSphere.  7 (2023)  S3 - p. e852670f , 2023
Link: https://doi.org/10.1097/..
 
?
8

Early efficacy and safety of obinutuzumab with chemotherapy..:

Paszkiewicz-Kozik, Ewa ; Hus, Iwona ; Palka, Monika...
Advances in Clinical and Experimental Medicine.  32 (2023)  1 - p. 131-136 , 2023
Link: https://doi.org/10.17219..
 
?
9

Clinical efficacy and tolerability of venetoclax plus ritux..:

Soboń, Anita ; Drozd-Sokołowska, Joanna ; Paszkiewicz-Kozik, Ewa...
Annals of Hematology.  102 (2023)  8 - p. 2119-2126 , 2023
Link: https://doi.org/10.1007/..
 
?
10

P526: SAFETY AND EFFICACY UPDATE FROM CLI120-001: A PHASE1B..:

Lech-Marańda, Ewa ; Szymańska, Agata ; Zaucha, Jan...
HemaSphere.  7 (2023)  S3 - p. e27994b8 , 2023
Link: https://doi.org/10.1097/..
 
?
11

CRL4CRBN E3 Ligase Complex as a Therapeutic Target in Multi..:

Barankiewicz, Joanna ; Salomon-Perzyński, Aleksander ; Misiewicz-Krzemińska, Irena.
Cancers.  14 (2022)  18 - p. 4492 , 2022
Link: https://doi.org/10.3390/..
 
?
12

MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Re..:

Cohen, Jonathon B. ; Shah, Nirav N. ; Alencar, Alvaro J....
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S394-S395 , 2022
Link: https://doi.org/10.1016/..
 
?
13

CLL-120 Pirtobrutinib, A Highly Selective, Non-Covalent (Re..:

Coombs, Catherine C. ; Pagel, John M. ; Shah, Nirav N....
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S268-S269 , 2022
Link: https://doi.org/10.1016/..
 
?
14

Targeting arginase-1 exerts antitumor effects in multiple m..:

Ramji, Kavita ; Grzywa, Tomasz M. ; Sosnowska, Anna...
Scientific Reports.  12 (2022)  1 - p. , 2022
Link: https://doi.org/10.1038/..
 
?
15

Poster: MCL-133 Pirtobrutinib, a Highly Selective, Non-Cova..:

Cohen, Jonathon B. ; Shah, Nirav N. ; Alencar, Alvaro J....
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S175 , 2022
Link: https://doi.org/10.1016/..
 
1-15